The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
about
Prehospital stroke scales as screening tools for early identification of stroke and transient ischemic attackThrombolysis for acute ischaemic strokeRecombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisMinor Stroke and Transient Ischemic Attack: Research and PracticeAngiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal MedicineCombined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic strokeImproving post-stroke recovery: the role of the multidisciplinary health care teamAbsolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom OnsetEffect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsReperfusion therapy of acute ischaemic stroke and acute myocardial infarction: similarities and differencesCase characteristics, hyperacute treatment, and outcome information from the clinical research center for stroke-fifth division registry in South KoreaThe exact science of stroke thrombolysis and the quiet art of patient selectionThe fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015Using publication metrics to highlight academic productivity and research impactHow individual participant data meta-analyses have influenced trial design, conduct, and analysisReview article: Why is there still a debate regarding the safety and efficacy of intravenous thrombolysis in the management of presumed acute ischaemic stroke? A systematic review and meta-analysis.Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.Reperfusion therapies for acute ischemic stroke: an updateAcute Stroke Imaging Research Roadmap II.Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic strokeManagement of ischaemic stroke in the acute setting: review of the current status.Selection of possible responders to thrombolytic therapy in acute ischemic stroke.Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials.Can online benchmarking increase rates of thrombolysis? Data from the Austrian stroke unit registry.Review of stroke thrombolytics.Experimental models of brain ischemia: a review of techniques, magnetic resonance imaging, and investigational cell-based therapies.Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials.Imaging of acute stroke prior to treatment: current practice and evolving techniques.Intravenous thrombolysis for acute ischaemic stroke in the elderly: data from the Baden-Wuerttemberg stroke registry.Stroke Treatment Academic Industry Roundtable Recommendations for Individual Data Pooling Analyses in StrokeThrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data?Clinical Outcome after Intra-Arterial Stroke Therapy in the Very Elderly: Why is it so Heterogeneous?Stroke thrombolysis at 5.5 hours based on computed tomography perfusionReceptionist rECognition and rEferral of PaTients with Stroke (RECEPTS) study - protocol of a mixed methods study.Intravenous Thrombolysis in Chinese Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild StrokePrediction of stroke thrombolysis outcome using CT brain machine learning.Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic AgentsDrug-induced hypothermia in stroke models: does it always protect?Blood Pressure and Penumbral Sustenance in Stroke from Large Vessel Occlusion.
P2860
Q24187522-74C42BFC-E5EC-4558-93AC-932F8A16120AQ24194788-3D617212-034A-4A41-AAE8-391C77B6A66CQ24595703-9E22AD5D-7036-4BCD-B1AE-94B8C6654CEAQ26745201-BBCD356D-AA7F-4B69-9639-DBE711184C91Q26747497-B6549871-4B43-42C0-A0D7-700942859F3BQ26782990-894974A0-FC28-4367-BDAF-56C2F83EF69EQ26786565-7D99AE63-B316-456B-931A-25A43FC9AA9BQ26796474-004E6FF0-44DB-4946-BEA7-028D4DAD16EDQ26796477-EF8A7684-4D45-4838-AECF-CF4314891612Q26823902-065A1BA2-C814-43C2-AF08-2E4923A2D823Q26824552-D363D4FE-35F4-4246-BC85-226887C97279Q27011252-5437B427-9435-4DB7-80E0-09DE79D32344Q27011873-95603CC6-D899-4262-B84D-84C2CF1A4747Q28069442-7703774A-E59A-4A0C-98D4-CBA4EC39FCF0Q28597772-53065C01-1209-49F3-A954-40C0E282F01BQ28607751-D9E140F8-CF22-4BA4-9176-9A1A4616ABA2Q30248290-68A045E8-A47F-452F-9C8F-BF116009F26EQ30275531-B446BA51-CAD1-401E-AFDC-B53CEE19A634Q30399762-E11375C0-8E73-4337-A1E8-FE2444565E7BQ30411115-5BD64760-C6FF-48B8-A353-78916C28FEE0Q30414441-81B8E2EC-DFF7-4866-9222-059F4B72576BQ30431467-7D03E0F3-D1D6-4F49-8D71-0D33DF4FF3E2Q30568984-9D0C98DC-0723-4EAB-BB7B-2D850DA8408DQ30621033-EFA7919F-1A78-46C0-8390-6DC2F9289288Q30643480-F9AD810E-E3A4-43BC-9BBD-6B375C867C85Q30712454-87DF4E7D-2E52-4715-9069-0C9D360F7D0FQ30771799-5E6D6B0E-9CC0-4A98-9C99-E77439EFA56AQ30827853-316BF97B-04D7-4C4D-81C3-A0D3AD2A2816Q30831710-BE9B1B31-6A0C-4A6E-BE47-CC77BF1867C0Q31009812-6965DD3F-0815-4491-A8EA-BFCE93CCFB44Q31114160-F02BE0FA-2777-4BFC-A984-C69849982334Q31156580-B0527695-1F5F-488F-91B4-C16C02D132D9Q33569164-D520E2A9-85F9-4DE4-92D3-AC4FA1717F0AQ33639824-89A455E8-789D-4CBC-A687-3C1D97742CC4Q33646557-5C370D58-D674-4340-8E96-C600247104BCQ33720130-070AEBCB-19A4-49CC-BDC6-AC1F22C1EA6BQ33741379-B499991E-4B19-4246-B7FC-9172743A9342Q33783563-16B060B9-6EBF-4DD7-ADE6-D6D2E2D611B9Q33844760-6962B4DE-2D8A-48C8-952B-FB6EDE9DAD2AQ33863549-64ACAFF0-BC2D-45B5-9CF9-2912BAD04F93
P2860
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The benefits and harms of intr ...... a randomised controlled trial
@ast
The benefits and harms of intr ...... a randomised controlled trial
@en
The benefits and harms of intr ...... a randomised controlled trial
@nl
type
label
The benefits and harms of intr ...... a randomised controlled trial
@ast
The benefits and harms of intr ...... a randomised controlled trial
@en
The benefits and harms of intr ...... a randomised controlled trial
@nl
prefLabel
The benefits and harms of intr ...... a randomised controlled trial
@ast
The benefits and harms of intr ...... a randomised controlled trial
@en
The benefits and harms of intr ...... a randomised controlled trial
@nl
P2093
P2860
P50
P3181
P1433
P1476
The benefits and harms of intr ...... a randomised controlled trial
@en
P2093
Adam Kobayashi
Andre Peeters
Antonio Arauz
Geoff Cohen
Graham Venables
Karen Innes
Karsten Bruins Slot
Manuel Correia
Martin Dennis
P2860
P304
P3181
P356
10.1016/S0140-6736(12)60768-5
P407
P50
P577
2012-06-23T00:00:00Z